# NATURAL PRODUCTS

# Triterpene Galactosides of the Pouoside Class and Corresponding Aglycones from the Sponge *Lipastrotethya* sp.

Jung-Ho Lee,<sup>†</sup> Kyoung Hwa Jang,<sup>†</sup> Yeon-Ju Lee,<sup>‡</sup> Hyi-Seung Lee,<sup>‡</sup> Chung J. Sim,<sup>§</sup> Ki-Bong Oh,<sup>\*,⊥</sup> and Jongheon  $h^{*,^{\dagger}}$ 

<sup>†</sup>Natural Products Research Institute, College of Pharmacy, Seoul National University, San 56-1, Sillim, Gwanak, Seoul 151-742, Korea

<sup>‡</sup>Marine Natural Products Laboratory, Korea Ocean Research & Development Institute, P.O. Box 29, Seoul 425-600, Korea

<sup>§</sup>Department of Biological Science, College of Life Science and Nano Technology, Hannam University, 461-6, Jeonmin, Yuseong, Daejeon 305-811, Korea

<sup>⊥</sup>Department of Agricultural Biotechnology, College of Agriculture and Life Science, Seoul National University, San 56-1, Sillim, Gwanak, Seoul 151-921, Korea

# **Supporting Information**



**ABSTRACT:** Nine new triterpene galactosides and aglycones, along with three known compounds from the rare pouoside class, were isolated from the tropical sponge *Lipastrotethya* sp. collected from Micronesia. The structures of these new compounds were determined by combined spectroscopic methods and designated as pouosides F-I (4, 8, 10, and 12) and pouogenins A-E (5–7, 9, and 11). The absolute configurations of the asymmetric centers and the cyclohexenone moiety, which had been previously undetermined, were assigned by NOESY analyses and Mosher's methods. Several of these compounds exhibited weak cytotoxicity against the K562 cell line.

Marine sponges produce a wide variety of terpenes and related metabolites possessing diverse carbon skeletons and bioactivities.<sup>1</sup> However, triterpenes and triterpene saponins are relatively rare and represent only a minor fraction of the known sponge-derived terpenoids. Of these compounds, pouosides are a class of cytotoxic triterpene galactosides that have been isolated from the tropical sponge *Asteropus* sp. collected from the Truk Lagoon.<sup>2</sup> The symmetric carbon skeletons of these compounds are reminiscent of carotenoids and are unique among sponge-derived terpenoids. Despite the numerous works on marine sponges, compounds of this structural class have not been investigated since the first report on pouosides A–E by Schmitz<sup>2</sup> several decades ago.

During the course of our search for bioactive metabolites from tropical marine organisms, we encountered the sponge *Lipastrotethya* sp. (order Halichondrida, family Dictyonellidae), the organic extract of which exhibited weak cytotoxicity (LC<sub>50</sub> 146  $\mu$ g/mL) against the K562 cell line. Bioassay-guided separation of the extract yielded sarasinosides, widely recognized nortriterpene pentaglycosides, as the major constituents.<sup>3–9</sup> However, moderately polar vacuum flash chromatographic fractions yielded several compounds of a different structural class. Here we report the structures of nine new triterpenes of the pouoside class along with three other known compounds of the same structural class (1-3).<sup>2</sup> The new compounds were designated as the new triterpene galactosides pouosides F–I (4, 8, 10, and 12) and their aglycones, pouogenins A–E (5–7, 9, and 11), respectively. In addition, the absolute configurations of the asymmetric carbon centers and the cyclohexenone moiety were determined for the first time using a series of Mosher's esterification methods and NOESY analyses. Several of these compounds showed weak cytotoxicity against the K562 cell line.

# RESULTS AND DISCUSSION

The sponge samples were lyophilized, macerated, and repeatedly extracted with  $CH_2Cl_2$  and MeOH. The combined extracts were separated by solvent-partitioning followed by ODS vacuum flash chromatography and then repeated ODS-

Received:September 19, 2011Published:December 7, 2011



© 2011 American Chemical Society and American Society of Pharmacognosy and American Society of Pharmacognosy Chart 1





HPLC. The major constituents were identified as sarasinosides  $A_1$  and  $A_3$  by combined spectroscopic methods and a comparison of <sup>1</sup>H and <sup>13</sup>C NMR data with authentic samples.<sup>5,7</sup>

In addition to the sarasinosides, 12 other compounds were isolated by the same HPLC separation methods. The structures of compounds 1-3 were identified as pouosides A, D, and B, respectively, on the basis of spectroscopic analyses and a comparison of NMR data with the literature.<sup>2</sup>

The molecular formula of pouoside F (4) was  $C_{38}H_{62}O_{11}$  as determined by HRFABMS analysis. The <sup>13</sup>C and <sup>1</sup>H NMR data of this compound were similar to those of 1 and implied a monoacetylated triterpene glycoside. The triterpene nature of this compound was revealed by the presence of eight upfield methyl signals in the NMR data (Tables 1 and 2). Also, the <sup>13</sup>C NMR spectrum contained signals corresponding to a ketone ( $\delta_C$  217.4), an acetoxy group ( $\delta_C$  172.2 and 23.0), and three double bonds (six signals at  $\delta_C$  141.0–119.0), which were precisely matched with their corresponding signals in the <sup>1</sup>H NMR spectrum and absorption bands at 1730 and 1710 cm<sup>-1</sup> in the IR spectrum. Similarly, the presence of a sugar unit was revealed by characteristic signals at of  $\delta_C$  107.3 and 77–62 and  $\delta_H$  4.3–3.4. Overall, these NMR features clearly indicated that 4 was an analogue of pouoside A (1).

Given this information, the structure of 4 was determined by a combination of 2-D NMR experiments. First, the presence of a sugar moiety was secured by a combination of COSY and gHSQC data for the signals in the aforementioned NMR regions. Similarities in the chemical shifts and splitting patterns of these signals with those of 1 suggested the presence of a Dgalactose group that was confirmed by hydrolysis of 4 followed by GC analysis with authentic sugars. The pyranose nature of this galactose group was supported by long-range correlations at H-1'/C-5' and H-5'/C-1' in the gHMBC data. In addition, the  $\beta$ -configuration at the anomeric center was also assigned by its carbon chemical shift ( $\delta_C$  107.3) and large <sup>1</sup>H/<sup>1</sup>H coupling constant ( $J'_{1,2}$ ' = 7.5 Hz). Taken together, these data indicate the presence of a  $\beta$ -D-galactopyranose unit on compound 4.

The structure of the aglycone was also determined by combined NMR analyses. In particular, several long-range correlations between upfield methyl protons and neighboring ring carbons in the gHMBC data revealed the presence of 4,6,6trimethyl- $\beta$ , $\gamma$ -cyclohexenone (C-1–C-6) and 1,1,4-trimethylcyclohexane (C-17–C-22) moieties. The downfield shift of C-19 at  $\delta_{\rm C}$  89.0, the HMBC correlation H-19/C-1', and the NOESY cross-peak at H-19/H-1' indicated a galactose moiety at this location via a glycosidic linkage.

The remaining part of the molecule, including two trisubstituted double bonds, two oxymethine groups, and two vinyl methyl groups, made up a linear terpenoidal chain (C-7–C-16) based on COSY (H-7–H-8, H-10–H-13, H-15–H-16) and gHMBC (H-8/C-7, C-9, C-10, C-26; H-11/C-9, C-10, C-12, C-13; H-26/C-8, C-9, C-10; H-27/C-13, C-14, C-15) data. Connections of this chain with the cyclic moieties were also established with these data: COSY (H-6–H-8, H-15–H-17) and gHMBC (H-6/C-7, C-8; H-8/C-6; H-15/C-17). Of the oxygenated locations at C-8, C-11, and C-22, the remaining acetoxy group was placed at C-22 by the proton chemical shifts of H-8 ( $\delta_{\rm H}$  3.95) and H-11 ( $\delta_{\rm H}$  4.32). Thus, pouoside F (4) was identified as a triterpene galactoside.

Pouoside F possessed asymmetric double bonds at C-9 and C-13. The geometries at these bonds were both E on the basis of the upfield shifts of vinyl methyl carbons ( $\delta_{\rm C}$  13.0 and 16.7 for C-26 and C-27, respectively) and cross-peaks at H-8/H-10, H-11/H-26, H-12/H-27, and H-13/H-15 in the NOESY data. This compound also possessed asymmetric carbon centers at C-6, C-8, C-11, C-17, C-19, and C-22, whose relative configurations had previously only been partially determined. Among these, the relative configurations of those in the sixmembered rings and vicinity were assigned by proton coupling constants and NOESY analyses. First the anti-orientations were assigned for both H-6/H-7b ( $\delta_{\rm H}$  1.14) and H-7a ( $\delta_{\rm H}$  1.68)/H-8 by the large vicinal coupling constants ( $J_{6,7b}$  = 9.5 Hz,  $J_{7a,8}$  = 10.0 Hz). Given this information, the NOESY data showed cross-peaks at H-4/H-23, H-6/H23, H-24, H-25, and H-23/H-25, placing H-6 at the pseudoequatorial position in the cyclohexenone ring. Additional NOE cross-peaks were found at H-6/H-8, H-7a/H-24, H-8/H-25, H-26, H-10/H-7a, H-24, and H-25/H-26, supporting the 6R\* and 8S\* configurations. More crucial evidence was found from NOESY data obtained in pyridine- $d_5$  (Supporting Information). The 8-OH proton at  $\delta$ 

#### Journal of Natural Products

Table 1. <sup>1</sup>	<sup>3</sup> C NMR	(ppm, mult	) Assignments f	or Compound	ls 4–12 in (	$D_3OD$
-----------------------	--------------------	------------	-----------------	-------------	--------------	---------

position	4	5	6	7	8	9	10	11	12
1	48.6, C	48.7, C	48.6, C	48.6, C	46.7, C	46.7, C	46.7, C	46.8, C	48.9, C
2	217.4, C	217.3, C	216.6, C	216.7, C	206.2, C	206.2, C	205.8, C	205.8, C	216.7, C
3	38.7, CH <sub>2</sub>	39.0, CH <sub>2</sub>	38.7, CH <sub>2</sub>	38.9, CH <sub>2</sub>	125.3, CH	125.3, CH	125.5, CH	125.6, CH	38.2, CH <sub>2</sub>
4	119.0, CH	118.9, CH	119.6, CH	119.6, CH	158.0, CH	158.0, CH	157.7, CH	157.7, CH	119.5, CH
5	141.0, C	141.0, C	139.2, C	139.5, C	72.0, C	72.0, C	71.6, C	71.7, C	139.3, C
6	50.0, CH	50.0, CH	51.0, CH	51.1, CH	50.0, CH	50.0, CH	51.1, CH	51.1, CH	51.0, CH
7	38.8, CH <sub>2</sub>	38.8, CH <sub>2</sub>	35.6, CH <sub>2</sub>	36.0, CH <sub>2</sub>	31.0, CH <sub>2</sub>	31.0, CH <sub>2</sub>	35.1, CH <sub>2</sub>	35.1, CH <sub>2</sub>	35.6, CH <sub>2</sub>
8	75.6, CH	75.6, CH	78.4, CH	78.4, CH	80.3, CH	80.3, CH	203.8, C	203.8, C	78.4, CH
9	141.0, C	141.0, C	139.2, C	139.5, C	137.1, C	137.1, C	137.7, C	137.8, C	139.1, C
10	129.1, CH	129.1, CH	127.6, CH	131.6, CH	131.5, CH	131.5, CH	144.0, CH	144.0, CH	127.6, CH
11	69.2, CH	69.1, CH	72.0, CH	68.9, CH	68.9, CH	68.9, CH	69.6, CH	69.6, CH	72.2, CH
12	37.3, CH <sub>2</sub>	37.3, CH <sub>2</sub>	34.1, CH <sub>2</sub>	37.2, CH <sub>2</sub>	37.2, CH <sub>2</sub>	37.2, CH <sub>2</sub>	36.5, CH <sub>2</sub>	36.5, CH <sub>2</sub>	34.0, CH <sub>2</sub>
13	121.0, CH	121.0, CH	119.5, CH	120.7, CH	120.7, CH	120.7, CH	120.0, CH	120.1, CH	119.5, CH
14	139.0, C	139.0, C	140.6, C	139.3, C	139.2, C	139.2, C	139.9, C	140.0, C	140.2, C
15	44.0, CH <sub>2</sub>	44.0, CH <sub>2</sub>	43.9, CH <sub>2</sub>	44.0, CH <sub>2</sub>	44.1, CH <sub>2</sub>	44.1, CH <sub>2</sub>	43.8, CH <sub>2</sub>	44.0, CH <sub>2</sub>	39.7, CH <sub>2</sub>
16	26.4, CH <sub>2</sub>	26.5, CH <sub>2</sub>	26.6, CH <sub>2</sub>	26.6, CH <sub>2</sub>	26.4, CH <sub>2</sub>	26.6, CH <sub>2</sub>	26.3, CH <sub>2</sub>	26.5, CH <sub>2</sub>	24.8, CH <sub>2</sub>
17	54.5, CH	54.3, CH	54.3, CH	54.4, CH	54.4, CH	54.4, CH	54.4, CH	54.3, CH	52.7, CH
18	42.1, C	41.7, C	41.8, C	41.8, C	42.1, C	41.8, C	42.0, C	41.8, C	42.0, C
19	89.0, CH	78.3, CH	78.3, CH	78.4, CH	88.9, CH	78.4, CH	88.9, CH	78.4, CH	88.4, CH
20	28.3, CH <sub>2</sub>	28.7, CH <sub>2</sub>	29.0, CH <sub>2</sub>	29.0, CH <sub>2</sub>	28.3, CH <sub>2</sub>	29.0, CH <sub>2</sub>	28.2, CH <sub>2</sub>	29.0, CH <sub>2</sub>	32.4, CH <sub>2</sub>
21	36.3, CH <sub>2</sub>	36.4, CH <sub>2</sub>	36.2, CH <sub>2</sub>	36.4, CH <sub>2</sub>	34.0, CH <sub>2</sub>				
22	88.2, C	88.3, C	88.3, C	88.4, C	88.2, C	88.3, C	88.2, C	88.3, C	149.4, C
23	26.0, CH <sub>3</sub>	25.9, CH <sub>3</sub>	26.5, CH <sub>3</sub>	26.4, CH <sub>3</sub>	25.3, CH <sub>3</sub>	25.2, CH <sub>3</sub>	25.1, CH <sub>3</sub>	25.1, CH <sub>3</sub>	26.5, CH <sub>3</sub>
24	21.6, CH <sub>3</sub>	21.6, CH <sub>3</sub>	21.7, CH <sub>3</sub>	21.6, CH <sub>3</sub>	22.1, CH <sub>3</sub>	22.1, CH <sub>3</sub>	21.8, CH <sub>3</sub>	21.8, CH <sub>3</sub>	21.7, CH <sub>3</sub>
25	25.0, CH <sub>3</sub>	24.9, CH <sub>3</sub>	23.9, CH <sub>3</sub>	24.1, CH <sub>3</sub>	23.3, CH <sub>3</sub>	23.3, CH <sub>3</sub>	23.2, CH <sub>3</sub>	23.1, CH <sub>3</sub>	23.9, CH <sub>3</sub>
26	13.0, CH <sub>3</sub>	12.9, CH <sub>3</sub>	13.0, CH <sub>3</sub>	13.1, CH <sub>3</sub>	13.1, CH <sub>3</sub>	13.0, CH <sub>3</sub>	12.8, CH <sub>3</sub>	12.9, CH <sub>3</sub>	13.0, CH <sub>3</sub>
27	16.7, CH <sub>3</sub>	16.6, CH <sub>3</sub>	16.6, CH <sub>3</sub>	16.7, CH <sub>3</sub>	16.7, CH <sub>3</sub>	16.7, CH <sub>3</sub>	16.6, CH <sub>3</sub>	16.7, CH <sub>3</sub>	16.5, CH <sub>3</sub>
28	28.6, CH <sub>3</sub>	29.0, CH <sub>3</sub>	28.8, CH <sub>3</sub>	28.8, CH <sub>3</sub>	28.6, CH <sub>3</sub>	28.8, CH <sub>3</sub>	28.5, CH <sub>3</sub>	28.8, CH <sub>3</sub>	26.7, CH <sub>3</sub>
29	16.7, CH <sub>3</sub>	16.0, CH <sub>3</sub>	16.1, CH <sub>3</sub>	16.1, CH <sub>3</sub>	16.7, CH <sub>3</sub>	16.1, CH <sub>3</sub>	16.6, CH <sub>3</sub>	16.0, CH <sub>3</sub>	17.5, CH <sub>3</sub>
30	20.5, CH <sub>3</sub>	20.4, CH <sub>3</sub>	20.4, CH <sub>3</sub>	21.2, CH <sub>3</sub>	20.4, CH <sub>3</sub>	20.4, CH <sub>3</sub>	20.5, CH <sub>3</sub>	20.3, CH <sub>3</sub>	108.6, CH <sub>2</sub>
1'	107.3, CH				107.3, CH		107.2, CH		107.3, CH
2'	73.1, CH				73.1, CH		73.1, CH		73.2, CH
3′	75.2, CH				75.2, CH		75.2, CH		75.3, CH
4'	70.3, CH				70.3, CH		70.3, CH		70.3, CH
5'	76.5, CH				76.5, CH		76.4, CH		76.4, CH
6'	62.5, CH <sub>2</sub>				62.5, CH <sub>2</sub>		62.5, CH <sub>2</sub>		62.4, CH <sub>2</sub>
8-OAc			171.7, C	171.9, C	172.1, C	172.1, C			171.8, C
			21.1, CH <sub>3</sub>	21.2, CH <sub>3</sub>	21.3, CH <sub>3</sub>	21.3, CH <sub>3</sub>			21.1, CH <sub>3</sub>
11-OAc			172.1, C						172.2, C
			21.2, CH <sub>3</sub>						21.2, CH <sub>3</sub>
22-OAc	172.2, C	172.1, C							
	23.0, CH <sub>3</sub>	22.9, CH <sub>3</sub>	23.0, CH <sub>3</sub>	23.0, CH <sub>3</sub>	23.0, CH <sub>3</sub>	23.0, CH <sub>3</sub>	22.9, CH <sub>3</sub>	23.0, CH <sub>3</sub>	

6.35 showed cross-peaks at 8-OH/H-6, H-7a, H-8, H-10, H-24, H-25, and H-26. Among these, the cross-peak at 8-OH/H-6 was crucial for ruling out the alternative 6S\* and 8S\* configurations (Figure 1). Similarly the NOESY data of the cyclohexane moiety showed conspicuous cross-peaks at H-17/ H-19, H-17/H-21 $\beta$  ( $\delta_{\rm H}$  1.77), H-17/H-28, H-19/H-21 $\beta$ , H-19/ H-28, H-20 $\alpha$  ( $\delta_{\rm H}$  1.57)/H-21 $\alpha$  ( $\delta_{\rm H}$  2.48), H-20 $\alpha$ /H-29, H-21 $\alpha$ /H-30, and H-29/H-30. These 1,3-diaxial-type cross-peaks readily established the 17S\*, 19S\*, 22S\* configurations (Figure 1). The absolute configurations at these centers and the remaining C-11 were determined by a series of Mosher esterification reactions and are discussed below along with those of the other compounds.

The molecular formula of pouogenin A (5) was  $C_{32}H_{52}O_6$  on the basis of HRFABMS data. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of this compound were similar to those of 4 except, most noticeably, for the absence of signals corresponding to the

galactose unit. This interpretation was confirmed by a combination of 2-D NMR experiments and further supported by the shift of the H-19 oxymethine proton (4:  $\delta_{\rm C}$  89.0,  $\delta_{\rm H}$  3.30; 5:  $\delta_{\rm C}$  78.3,  $\delta_{\rm H}$  3.27). Thus, 5 was structurally defined as the aglycone of 4.

A structurally related compound, pouogenin B (6), was isolated as a colorless oil with the molecular formula  $C_{36}H_{56}O_8$  as determined by HRFABMS. As for 5, the absence of a sugar unit was apparent from the NMR data, implying that 6 is a triterpene triacetate. A combination of 2-D NMR data showed that this compound was the aglycone of 1. This conclusion is consistent with noticeable shifts of the H-19 oxymethine proton (1:  $\delta_C$  89.0,  $\delta_H$  3.30; 6:  $\delta_C$  78.3,  $\delta_H$  3.27) as well as downfield shifts of the H-8 and H-11 oxymethine protons (5:  $\delta$  3.95 and 4.32; 6:  $\delta$  4.97 and 5.41 for H-8 and H-11, respectively) from that of 5.

#### Table 2. <sup>1</sup>H MMR ( $\delta$ , mult (J in Hz)) Assignments for Compounds 4–7 in CD<sub>3</sub>OD

position	4	5	6	7
3	2.89, ddq (22.5, 4.5, 1.0)	2.89, ddq (22.5, 4.5, 1.0)	2.93, ddq (22.5, 4.5, 1.0)	2.93, ddq (22.5, 4.5, 1.0)
	2.71, ddq (22.5, 3.0, 1.0)	2.72, ddq (22.5, 3.0, 1.0)	2.72, ddq (22.5, 3.0, 1.0)	2.72, ddq (22.5, 3.0, 1.0)
4	5.50, m	5.49, m	5.47, m	5.48, m
6	2.27, dd (9.5, 4.5)	2.27, dd (9.5, 4.5)	2.12, dd (6.5, 5.0)	2.16, dd (8.0, 4.5)
7	1.68, ddd (13.5, 10.0, 4.5)	1.68, ddd (13.5, 10.0, 4.5)	1.88, ddd (14.5, 9.0, 5.0)	1.92, ddd (14.5, 10.0, 4.5)
	1.14, ddd (13.5, 9.5, 3.0)	1.15, ddd (13.5, 9.5, 3.0)	1.42, ddd (14.5, 6.5, 4.5)	1.42, ddd (14.5, 8.0, 3.0)
8	3.95, dd (10.0, 3.0)	3.95, dd (10.0, 3.0)	4.97, dd (9.0, 4.5)	4.96, dd (10.0, 3.0)
10	5.37, br d (9.0)	5.37, br d (9.0)	5.32, br d (9.0)	5.33, br d (9.0)
11	4.32, ddd (9.0, 7.0, 6.5)	4.32, ddd (9.0, 7.0, 6.5)	5.41, ddd (9.0, 7.0, 6.5)	4.30, ddd (9.0, 7.0, 6.5)
12	2.29, ddd (14.0, 7.0, 6.5)	2.29, ddd (14.0, 7.0, 6.5)	2.39, ddd (14.0, 7.0, 6.5)	2.29, ddd (14.0, 7.0, 6.5)
	2.14, ddd (14.0, 7.0, 7.0)	2.15, ddd (14.0, 7.0, 7.0)	2.24, ddd (14.0, 7.0, 7.0)	2.13, ddd (14.0, 7.0, 7.0)
13	5.17, br t (7.0)	5.18, br t (7.0)	5.08, br t (7.0)	5.12, br t (7.0)
15	2.14, m	2.15, m	2.14, ddd (12.5, 12.5, 5.0)	2.15, m
	2.01, ddd (12.5, 12.5, 5.0)	2.01, ddd (12.5, 12.5, 5.0)	2.00, m	1.98, ddd (12.5, 12.5, 5.0)
16	1.55, m	1.55, m	1.51, m	1.56, m
	1.46, m	1.46, m	1.44, m	1.46, m
17	1.60, m	1.57, m	1.56, m	1.57, m
19	3.30, dd (11.5, 4.0)	3.27, dd (11.5, 4.0)	3.27, dd (11.5, 4.0)	3.27, dd (11.5, 4.0)
20	2.06, dddd (13.5, 4.0, 4.0, 4.0)	1.68, dddd (13.5, 4.0, 4.0, 4.0)	1.69, dddd (13.5, 4.0, 4.0, 4.0)	1.69, dddd (13.5, 4.0, 4.0, 4.0)
	1.57, dddd (13.5, 11.5, 11.5, 4.0)	1.53, dddd (13.5, 11.5, 11.5, 4.0)	1.54, dddd (13.5, 11.5, 11.5, 4.0)	1.53, dddd (13.5, 11.5, 11.5, 4.0)
21	2.48, ddd (13.5, 4.0, 4.0)	2.51, ddd (13.5, 4.0, 4.0)	2.52, ddd (13.5, 4.0, 4.0)	2.52, ddd (13.5, 4.0, 4.0)
	1.77, ddd (13.5, 11.5, 4.0)	1.77, ddd (13.5, 11.5, 4.0)	1.76, ddd (13.5, 11.5, 4.0)	1.77, ddd (13.5, 11.5, 4.0)
23	1.19, s	1.19, s	1.21, s	1.21, s
24	1.06, s	1.06, s	1.07, s	1.09, s
25	1.91, d (1.0)	1.91, d (1.0)	1.79, d (1.0)	1.81, d (1.0)
26	1.59, d (1.0)	1.60, d (1.0)	1.66, d (1.0)	1.61, d (1.0)
27	1.64, br s	1.64, br s	1.65, br s	1.63, br s
28	1.10, s	1.02, s	1.02, s	1.02, s
29	0.88, s	0.80, s	0.81, s	0.81, s
30	1.47, s	1.47, s	1.47, s	1.47, s
1'	4.28, d (7.5)			
2'	3.50, dd (7.5, 9.5)			
3'	3.43, dd (9.5, 3.5)			
4'	3.81, dd (3.5, 0.5)			
5'	3.48, dt (0.5, 6.0)			
6'	3.71, d (6.0)			
8-OAc			2.01, s	1.99, s
11-OAc			1.98, s	
22-OAc	1.93, s	1.93, s	1.93, s	1.93, s

The NMR spectroscopic features of another aglycone, pouogenin C (7) ( $C_{34}H_{54}O_7$ ), were similar to those of the other aglycones (Tables 1 and 2). 2-D NMR analyses revealed that this compound possessed the same carbon framework as **5** and **6** with structural differences occurring only in the oxygenated functionalities at C-8, C-11, or C-22. Proton chemical shifts and HMBC correlation analyses placed a hydroxy group at C-11 ( $\delta_H$  4.30) and acetoxy groups at C-8 and C-22, respectively. Thus, 7 was structurally defined as the aglycone of pouoside B (3), which is consistent with the chemical shifts of the oxymethine group at C-19 (**3**:  $\delta_C$  89.0,  $\delta_H$  3.30; 7:  $\delta_C$  78.4,  $\delta_H$  3.27).

The molecular formula of pouoside G (8) was deduced as  $C_{40}H_{64}O_{13}$  by HRFABMS. A detailed examination of its <sup>13</sup>C and <sup>1</sup>H NMR spectra revealed that this compound is another triterpene galactoside. However, significant differences were found in the carbon and proton signals of the cyclohexenone moiety (C-1–C-6). The carbon signals corresponding to the C-4 trisubstituted double bond were replaced with those of a disubstituted double bond [ $\delta_{\rm C}$  158.0 (CH) and 125.3 (CH)]. A

corresponding difference was also found in the <sup>1</sup>H NMR data, in which new signals appeared at  $\delta_{\rm H}$  6.73 (1H, d, J = 10.0 Hz) and 5.80 (1H, d, J = 10.0 Hz). In addition, the C-3 methylene carbon of 1–7 disappeared and there was a new C-5 quaternary carbon atom ( $\delta_{\rm C}$  72.0). These changes were accommodated by a migration of the C-4 double bond to C-3 and concomitant attachment of a hydroxy group at C-5. These changes were confirmed by 2-D NMR data including key long-range correlations at H-3/C-1, C-5, H-4/C-2, C-6, and H-25/C-4, C-5, C-6 in the gHMBC data. The relative configurations at C-5 and C-6 were established as  $5S^*$  and  $6S^*$  on the basis of cross-peaks at H-6/H-8, H-6/H-23 ( $\delta_{\rm H}$  1.21), H-7a ( $\delta_{\rm H}$  1.95)/ H-24, H-7a/H-25, H-7b ( $\delta_{\rm H}$  1.78)/H-23, H-7b/H-24 ( $\delta_{\rm H}$ 1.02), H-8/H-25, H-8/H-26, H-23/8-OAc, H-24/H-25, and H-25/H-26 in the NOESY data (Figure 1). Thus the structure of pouoside G (8) was that of a 3-ene-5-hydroxy derivative of pouoside B(2).

The aglycone of compound 8, pouogenin D (9), was also isolated as a colorless oil with a molecular formula of  $C_{34}H_{54}O_8$ . With the exception of signals derived from the galactose

#### **Journal of Natural Products**



Figure 1. Selected NOESY correlations for compounds 4 (a, b) and 8 (c).

moiety, the carbon and proton NMR data were very similar to those of **8**. All of the proton-proton and proton-carbon correlations observed in the 2-D NMR experiments were also virtually identical to those of **8**, and the removal of the galactose unit from C-19 was further confirmed by characteristic shifts of the methine (**8**:  $\delta_{\rm C}$  88.9,  $\delta_{\rm H}$  3.29, **9**:  $\delta_{\rm C}$  78.4,  $\delta_{\rm H}$  3.27).

The molecular formula of pouoside H (10) was established as  $C_{38}H_{60}O_{12}$  by HRFABMS. The NMR spectra of this compound were reminiscent of those of other pouosides, and particularly with those of **8**, with a galactose unit and two sixmembered rings as the most apparent structural features. However, the <sup>13</sup>C NMR data indicated oxidation of a hydroxymethine to a ketone ( $\delta$  203.8) that was consistent with the shift [**8**:  $\delta_{\rm H}$  5.45 (1H, dd, J = 9.0, 5.0 Hz); **10**:  $\delta_{\rm H}$  6.57 (1H, br d, J = 8.0 Hz)] of a proton signal in the <sup>1</sup>H NMR data. The ketone was placed at C-8 on the basis of long-range correlations at H-6/C-8, H-7/C-8, H-10/C-8, C-26, and H-26/ C-8, C-9, C-10 in the gHMBC data. Thus, the structure of pouoside H (**10**) was determined to be that of an 8-oxo analogue of pouoside G (**8**).

The aglycone of pouoside H (10), pouogenin E (11), was isolated as a colorless oil with a molecular formula of  $C_{32}H_{50}O_7$  based on HR-negative-FABMS analysis. As found for the other triterpene galactosides and corresponding aglycones, the NMR data of this compound were highly reminiscent of those obtained from pouoside H (10). On the basis of the results of combined NMR analyses, all of the carbons and protons are in the same locations as in 10 (Tables 2 and 3).

The molecular formula of another triterpene galactoside, pouoside I (12), was determined as  $C_{40}H_{62}O_{11}$  by mass analysis. The spectroscopic data of this compound were very similar to those of the other triterpene galactosides. However, the <sup>13</sup>C NMR spectrum revealed an exo-double bond [ $\delta$  149.4 (C), 108.6 (CH<sub>2</sub>)] that coincided with the exo-methylene protons [ $\delta$  4.84 (1H, br s), 4.55 (1H, br s)] in the <sup>1</sup>H NMR data. This group was securely established at C-22 (30) based on long-range correlations H-16/C-22, H-17/C-22, C-30, H-20/ C-22, H-21/C-22, C-30, and H-30/C-21, C-22 in the gHMBC data. The remainder of the structure, including the galactose moiety, was identical to that of 1 according to combined 2-D NMR analyses. Thus, the structure of pouoside I (12) was that of a 22-deacetoxy derivative of pouoside A (1).

A comparison of <sup>13</sup>C and <sup>1</sup>H NMR data revealed nearly identical chemical shifts for both carbons and protons among the core triterpenes of all the compounds 1-12 (Tables 1-3). Thus, the results of NOESY experiments indicated the same  $SS^*$ ,  $6R^*$  ( $6S^*$  for 8-11 but the same orientation with others),  $8S^*$ ,  $17S^*$ ,  $19S^*$ , and  $22S^*$  relative configurations at the same locations for these compounds. On the basis of a comparison of chemical shifts, the relative configuration at C-11, which was not determinable by NMR experiments, is also thought to be the same among these compounds.

Absolute configurations were assigned using Mosher's method on selected compounds. First, MTPA esterification of 3 with both (-)- and (+)-MTPA chloride unambiguously established the 11R configuration (Figure 2a). The same reactions with 4 resulted in the formation of bis-MTPA esters at the aglycone. Despite the proximity of the C-8 and C-11 asymmetric centers, the results clearly established 8S and 11R configurations based on differences in proton chemical shifts at H-10 and H-26. These two protons are located between two ester centers, and their chemical shifts were significantly different from those of the 3-MTPA esters. The chemical shifts of protons at the remaining locations were not significantly shifted (Figure 2b). Finally, a 19S configuration was established at the galactoside position by MTPA esterification of pouogenin C (7), and an 11R configuration was again confirmed by this reaction (Figure 2c). Thus, the absolute configurations of the asymmetric centers were unambiguously determined as 6R, 8S, 11R, 17S, 19S, and 22S (except 12) for 1–7 and 12 and 5S, 6S, 8S (except 10 and 11), 11R, 17S, 19S, and 22S for 8-11.

A previous paper on pouosides A–E reported moderate cytotoxicity of pouoside A toward a P388 cell-line  $(ED_{50} 1.5 \mu g/mL)$ .<sup>2</sup> The compounds reported herein exhibited weak to no activity against a K562 human erythroleukemia cell line  $(IC_{50} 17.0, 12.5, >100, >100, 14.8, 38.9, 14.6, >100, 27.5, >100, 18.9, and >100 \mu M$  for 1–12, respectively, n = 3; IC<sub>50</sub> 13.6  $\mu$ M for doxorubicin). With the exception of 1 and 2, the aglycones were far more cytotoxic than the triterpene galactosides. Compounds 5, 7, and 11, for example, showed inhibition properties comparable to those of doxorubicin against this cell line. None of these compounds showed significant antimicrobial activity against selected Gram-positive and Gram-negative bacteria and pathogenic fungi.<sup>10</sup>

### EXPERIMENTAL SECTION

**General Experimental Procedures.** Optical rotations were measured on a JASCO P-1020 polarimeter using a 1 cm cell. UV spectra were recorded on a Hitachi U-3010 spectrophotometer, and IR spectra were recorded in MeOH- $d_4$  containing Me<sub>4</sub>Si as an internal standard on Bruker Avance 500 and 600 spectrometers. Proton and carbon NMR spectra were measured at 600 and 150 MHz (4, 6, 8, 9, 11, and 12) and 500 and 125 MHz (5, 7, and 10), respectively. Mass spectrometer with *meta*-nitrobenzyl alcohol as a matrix for the FABMS. HPLC was performed on a SpectraSystem p2000 equipped with a SpectraSystem RI-150 refractive index detector. Gas chromatography was performed on a Younglin YL6100 Plus

# Table 3. <sup>1</sup>H MMR ( $\delta$ , mult (J in Hz)) Assignments for Compounds 8–12 in CD<sub>3</sub>OD

position	8	9	10	11	12
3	5.80, d (10.0)	5.80, d (10.0)	5.81, d (10.0)	5.82, d (10.0)	2.89, ddq (22.5, 4.5, 1.0) 2.68, ddq (22.5, 3.0, 1.0)
4	6.73, d (10.0)	6.73, d (10.0)	6.79, d (10.0)	6.77, d (10.0)	5.46, m
6	2.06, dd (7.0, 4.0)	2.06, dd (7.0, 4.0)	2.86, dd (8.0, 3.5)	2.86, dd (8.0, 3.5)	2.11, dd (6.5, 5.0)
7	1.95, ddd (15.0, 7.0, 5.0)	1.94, ddd (15.0, 7.0, 5.0)	3.00, dd (17.5, 8.0)	3.02, dd (17.5, 8.0)	1.87, ddd (14.5, 9.0, 5.0)
	1.78, ddd (15.0, 9.0, 4.0)	1.78, ddd (15.0, 9.0, 4.0)	2.85, dd (17.5, 3.5)	2.84, dd (17.5, 3.5)	1.42, ddd (14.5, 6.5, 4.5)
8	5.45, dd (9.0, 5.0)	5.45, dd (9.0, 5.0)	, , , ,	, , , ,	4.97, dd (9.0, 4.5)
10	5.39, br d (9.0)	5.39, br d (9.0)	6.57, br d (8.0)	6.57, br d (8.0)	5.31, br d (9.0)
11	4.34, ddd (9.0, 7.0, 6.0)	4.34, ddd (9.0, 7.0, 6.0)	4.54, ddd (8.0, 7.5, 6.5)	4.54, ddd (8.0, 7.5, 6.5)	5.39, ddd (9.0, 7.0, 6.5)
12	2.31, ddd (14.0, 7.0, 6.0)	2.30, ddd (14.0, 7.0, 6.0)	2.41, ddd (14.0, 7.5, 6.5)	2.41, ddd (14.0, 7.5, 6.5)	2.38, ddd (14.0, 7.0, 6.5)
	2.16, ddd (14.0, 7.0, 7.0)	2.15, ddd (14.0, 7.0, 7.0)	2.29, ddd (14.0, 7.5, 7.5)	2.28, ddd (14.0, 7.5, 7.5)	2.22, ddd (14.0, 7.0, 7.0)
13	5.15, br t (7.0)	5.16, br t (7.0)	5.19, br t (7.5)	5.19, br t (7.5)	5.03, br t (7.0)
15	2.14, m	2.14, m	2.14, ddd (12.5, 12.5, 5.0)	2.15, ddd (12.5, 12.5, 5.0)	2.04, m
	2.00, m	1.99, m	2.04, ddd (12.5, 12.5, 4.5)	2.02, ddd (12.5, 12.5, 4.5)	1.77, m
16	1.54, m	1.56, m	1.56, dddd (12.5, 12.5, 12.5, 5.0)	1.53, m	1.66, m
	1.47, m	1.46, m	1.44, m	1.44, dddd (12.5, 12.5, 5.0, 3.0)	1.55, m
17	1.61, m	1.57, m	1.59, m	1.55, m	1.67, m
19	3.29, dd (11.5, 4.0)	3.27, dd (11.5, 4.0)	3.28, dd (11.5, 4.0)	3.26, dd (11.5, 4.0)	3.35, dd (9.5, 4.5)
20	2.04, dddd (13.5, 4.0, 4.0, 4.0)	1.68, dddd (13.5, 4.0, 4.0, 4.0)	2.05, dddd (13.5, 4.0, 4.0, 4.0)	1.69, dddd (13.5, 4.0, 4.0, 4.0)	2.02, dddd (12.5, 4.5, 4.5, 4.5)
	1.59, dddd (13.5, 11.5, 11.5, 4.0)	1.53, dddd (13.5, 11.5, 11.5, 4.0)	1.58, dddd (13.5, 11.5, 11.5, 4.0)	1.52, dddd (13.5, 11.5, 11.5, 4.0)	1.64, m
21	2.47, ddd (13.0, 4.0, 4.0)	2.51, ddd (13.0, 4.0, 4.0)	2.48, ddd (13.5, 4.0, 4.0)	2.52, ddd (13.5, 4.0, 4.0)	2.31, ddd (12.5, 4.5, 4.5)
	1.78, ddd (13.0, 11.5, 4.0)	1.76, ddd (13.0, 11.5, 4.0)	1.76, ddd (13.5, 11.5, 4.0)	1.76, ddd (13.5, 11.5, 4.0)	1.95, ddd (12.5, 11.5, 4.5)
23	1.21, s	1.21, s	1.01, s	1.01, s	1.20, s
24	1.02, s	1.02, s	1.06, s	1.06, s	1.07, s
25	1.35, s	1.35, s	1.34, s	1.34, s	1.79, d (1.0)
26	1.71, d (1.0)	1.71, d (1.0)	1.80, d (1.0)	1.79, d (1.0)	1.66, d (1.0)
27	1.65, br s	1.65, br s	1.66, br s	1.66, br s	1.61, br s
28	1.10, s	1.02, s	1.09, s	1.01, s	1.07, s
29	0.89, s	0.81, s	0.88, s	0.80, s	0.79, s
30	1.47, s	1.47, s	1.47, s	1.46, s	4.84, br s
					4.55, br s
1'	4.27, d (7.5)		4.28, d (7.5)		4.27, d (7.5)
2'	3.49, dd (7.5, 9.5)		3.50, dd (7.5, 9.5)		3.51, dd (7.5, 9.5)
3'	3.42, dd (9.5, 3.5)		3.43, dd (9.5, 3.5)		3.43, dd (9.5, 3.5)
4′	3.81, dd (3.5, 0.5)		3.82, dd (3.5, 0.5)		3.82, d (3.5, 0.5)
5'	3.48, dt (0.5, 6.0)		3.48, dt (0.5, 6.0)		3.47, dt (0.5, 6.0)
6'	3.70, d (6.0)		3.71, d (6.0)		3.72, dd (6.0, 11.0)
					3.69, dd (6.0, 11.0)
8-OAc	2.02, s	2.02, s			2.01, s
11-OAc					1.99, s
22-OAc	1.93, s	1.93, s	1.92, s	1.91, s	

chromatograph equipped with an FID. All solvents were spectroscopic grade or distilled from glass prior to use.

Animal Material. Specimens of *Lipastrotethya* sp. (voucher collection number 102CH-232) were collected by hand using scuba equipment off the shore of Weno Island, Chuuk state, Federated States of Micronesia, at a depth of 15 m on February 18, 2010. The sponge was globular in shape and beige in alcohol, measured 130 × 170 mm, and was 45 mm thick. This structure was attached to the sea bottom by a few to several stalks up to 5 cm long and 1 cm in diameter. The surface was warty but smooth, and the texture was elastic in alcohol. The consistency was cartilaginous. The skeleton was a network of oxea and strongyle (400–1000 × 3–20  $\mu$ m). The specimens were similar to those of *Lipastrotethya rhaphoxea* de Laubenfels, 1954, in general morphology except that *L. rhaphoxea* had larger spicules, reaching 5000 × 15  $\mu$ m, with smaller spicules in the dermis measuring only 50 × 1  $\mu$ m. A voucher specimen (registry No. Spo. 57) was deposited at

the Natural History Museum, Hannam University, Korea, under the curatorship of C.J.S.

**Extraction and Isolation.** Freshly collected specimens were immediately frozen and stored at -25 °C until use. Lyophilized specimens were macerated and repeatedly extracted with MeOH (2 L × 3) and CH<sub>2</sub>Cl<sub>2</sub> (2 L × 3). The combined extracts (112.7 g) were successively partitioned between H<sub>2</sub>O (99.3 g) and *n*-BuOH (24.8 g); the latter fraction was repartitioned between H<sub>2</sub>O–MeOH (15:85) (13.72 g) and *n*-hexane (7.72 g). An aliquot of the former layer (5.70 g) was separated by C<sub>18</sub> reversed-phase vacuum flash chromatography using a sequential mixture of MeOH and H<sub>2</sub>O as eluents (six fractions in gradient, H<sub>2</sub>O–MeOH, from 50:50 to 0:100), acetone, and finally EtOAc.

On the basis of the results of <sup>1</sup>H NMR and cytotoxicity analyses, the fractions eluted with H<sub>2</sub>O–MeOH (30:70) (0.33 g), H<sub>2</sub>O–MeOH (20:80) (0.74 g), and H<sub>2</sub>O–MeOH (10:90) (1.10 g) were chosen for separation. The fraction eluted with H<sub>2</sub>O–MeOH (30:70) was





(c)

Figure 2. Results of MTPA esterification for compound 3, 4, and 7 (a-c).

separated by semipreparative reversed-phase HPLC (YMC-ODS column, 10 mm × 250 mm; H<sub>2</sub>O-MeOH, 35:65), yielding two peaks rich with secondary metabolites. Further purification of the first peak by reversed-phase HPLC (YMC-Pack CN column, 10 mm × 250 mm; H<sub>2</sub>O-MeOH, 65:35) provided compound 10 as a colorless oil, while purification of the second peak by reversed-phase HPLC (H2O-MeOH, 60:40) yielded compound 11.

The H<sub>2</sub>O-MeOH (20:80) fraction was separated by reversed-phase HPLC (YMC-ODS column; H<sub>2</sub>O-MeOH, 30:70) to yield, in order of elution, compounds 4, 8, 3, 5, and 9. These metabolites were then purified by reversed-phase HPLC (YMC-Pack CN column; H2O-MeOH, 65:35, for 4 and 8, and H<sub>2</sub>O-MeOH, 60:40, for 3, 5, and 9, respectively).

The H<sub>2</sub>O-MeOH (10:90) fraction was separated and purified by reversed-phase HPLC (YMC-ODS column; H2O-MeOH, 20:80), yielding, in order of elution, compounds 7, 1, 2, 6, and 12. These metabolites were then purified by HPLC (YMC-Pack CN column; H<sub>2</sub>O-MeOH, 50:50, for 1 and 7, H<sub>2</sub>O-MeCN, 62:38, for 2, and H<sub>2</sub>O-MeOH, 65:35, for 6 and 12, respectively). The purified metabolites were isolated in the following amounts: 48.0, 3.7, 72.4, 24.6, 17.0, 3.8, 20.2, 16.2, 17.8, 3.8, 4.6, and 3.5 mg of 1-12, respectively.

Pouoside A (1): colorless oil;  $[\alpha]_D^{25} - 26.2$  (c 0.50, MeOH). Pouoside D (2): colorless oil;  $[\alpha]_D^{25} - 25.8$  (c 0.48, MeOH). Pouoside B (3): colorless oil;  $[\alpha]_D^{25} - 40.8$  (c 0.65, MeOH). Pouoside F (4): colorless oil;  $[\alpha]_D^{25} - 29.0$  (c 0.35, MeOH); IR (ZnSe)  $\nu_{max}$  3400 (br), 1730, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 717.4194 [M + Na]<sup>+</sup> (calcd for C<sub>38</sub>H<sub>62</sub>O<sub>11</sub>Na, 717.4190).

Pouogenin A (5): colorless oil;  $[\alpha]_{D}^{25}$  -49.5 (c 0.40, MeOH); IR (ZnSe)  $\nu_{max}$  3420 (br), 1730, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 555.3663 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>52</sub>O<sub>6</sub>Na, 555.3662).

*Pouogenin B* (6): colorless oil;  $[\alpha]_D^{25}$  –24.0 (*c* 0.40, MeOH); IR (ZnSe)  $\nu_{max}$  3400 (br), 1733, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 639.3876 [M + Na]<sup>+</sup> (calcd for C<sub>36</sub>H<sub>56</sub>O<sub>8</sub>Na, 639.3873).

Pouogenin C (7): colorless oil;  $[\alpha]_D^{25}$  -26.3 (c 0.60, MeOH); IR (ZnSe)  $\nu_{\rm max}$  3450 (br), 1730, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 597.3771 [M + Na]<sup>+</sup> (calcd for C34H54O7Na, 597.3767).

Pouoside G (8): colorless oil;  $[\alpha]_{D}^{25}$  -13.4 (c 0.55, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ) 224 (2.42), 273 (1.45) nm; IR (ZnSe)  $\nu_{max}$  3400 (br), 1729, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 775.4247 [M + Na]<sup>+</sup> (calcd for C40H64O13Na, 775.4245).

Pouogenin D (9): colorless oil;  $[\alpha]_{D}^{25}$  -25.9 (c 0.55, MeOH); UV (MeOH)  $\lambda_{\rm max}$  (log  $\varepsilon$ ) 224 (2.41), 275 (1.47) nm; IR (ZnSe)  $\nu_{\rm max}$ 3430, 1730, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 613.3719 [M + Na]<sup>+</sup> (calcd for C<sub>34</sub>H<sub>54</sub>O<sub>8</sub>Na, 613.3716).

Pouoside H (10): colorless oil;  $[\alpha]_{D}^{25} - 11.5$  (c 0.25, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ) 224 (2.43), 275 (1.47) nm; IR (ZnSe)  $\nu_{max}$  3400 (br), 1728, 1711 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 731.3987  $[M + Na]^+$  (calcd for C<sub>38</sub>H<sub>60</sub>O<sub>12</sub>Na, 731.3982).

Pouogenin E (11): colorless oil;  $[\alpha]_{D}^{25}$  -5.0 (c 0.40, MeOH); UV (MeOH)  $\lambda_{max}$  (log  $\varepsilon$ ) 224 (2.43), 2.73 (1.46) nm; IR (ZnSe)  $\nu_{max}$ 3420, 1729, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 545.3484 [M - H]<sup>-</sup> (calcd for C<sub>32</sub>H<sub>49</sub>O<sub>7</sub>, 545.3478).

*Pouoside I* (12): colorless oil;  $[\alpha]_{D}^{25}$  -11.5 (c 0.35, MeOH); IR (ZnSe)  $\nu_{\text{max}}$  3430 (br), 1732, 1710 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Tables 1 and 2, respectively; HRFABMS m/z 741.4195 [M + Na]<sup>+</sup> (calcd for C<sub>40</sub>H<sub>62</sub>O<sub>11</sub>Na, 741.4190).

Esterification with  $(-)-(R)-\alpha$ -Methyoxy- $\alpha$ -(trifluoromethyl)phenylacetyl (MTPA) Chloride. Esterifications of compounds 3, 4, and 7 were carried out as follows. A total of 20  $\mu$ L of (-)-(R)-MTPA chloride was added to a solution containing 1.1-2.0 mg of the alcoholic compound in 100  $\mu$ L of dry pyridine. The mixture was allowed to stand under N2 at room temperature for 2 h. After the consumption of starting material was confirmed by thin-layer chromatography, 0.5 mL of H<sub>2</sub>O-MeOH (10:90) was added. The solvents were removed under vacuum, and the residue was separated by reversed-phase HPLC (YMC-ODS column, 10 mm × 250 mm; H<sub>2</sub>O-MeOH, 10:90) to give 1.0-2.1 mg of (S)-MTPA esters (3a, 4a, and 7a). The corresponding (R)-MTPA esters (3b, 4b, and 7b) were also obtained from the same esterification reactions with (+)-(S)-MTPA chloride. Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) of 3a:  $\delta_{\rm H}$ 5.675 (1 H, ddd, J = 9.0, 7.0, and 7.0 Hz, H-11), 5.279 (1 H, d, J = 9.0 Hz, H-10), 5.150 (1 H, dd, J = 7.0 and 7.0 Hz, H-13), 4.935 (1 H, dd, J = 9.5 and 3.5 Hz, H-8), 2.488 (1 H, ddd, J = 14.0, 7.0, and 7.0 Hz, H-12), 2.337 (1 H, ddd, J = 14.0, 7.0, and 7.0 Hz, H-12), 2.112 (1 H, m, H-6), 1.881 (1 H, m, H-7), 1.728 (3 H, s, H-26), 1.635 (3 H, s, H-27), and 1.366 (1 H, m, H-7); LR-ESIMS *m*/*z* 1624.7 [M + Na]<sup>+</sup> (calcd for  $C_{80}H_{92}F_{12}O_{20}Na$ , 1624.6). Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) of **3b**:  $\delta_{\rm H}$  5.675 (1 H, ddd, *J* = 9.0, 6.5, and 6.5 Hz, H-11), 5.407 (1 H, d, *J* = 9.0 Hz, H-10), 5.0554 (1 H, dd, *J* = 7.0 and 7.0 Hz, H-13), 4.958 (1 H, dd, J = 9.5 and 3.4 Hz, H-8), 2.403 (1 H, ddd, J = 14.0, 7.0, and 7.0 Hz, H-12), 2.285 (1 H, ddd, J = 14.0, 7.0, and 7.0 Hz, H-12), 2.140 (1 H, dd, J = 6.5 and 5.0 Hz, H-6), 1.899 (1 H, m, H-7), 1.747 (3 H, s, H-26), 1.571 (3 H, s, H-27), and 1.447 (1 H, m, H-7); LR-ESIMS m/z 1624.7  $[M + Na]^+$  (calcd for  $C_{80}H_{92}F_{12}O_{20}Na$ , 1624.6). Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) of 4a:  $\delta_{\rm H}$  5.719 (1 H, ddd, J = 9.0, 6.0, and 6.0 Hz, H-11), 5.432 (1 H, d, J = 9.0 Hz, H-10), 5.422 (1 H, br s, H-4), 5.270 (1 H, dd, J = 9.0 and 4.0 Hz, H-8), 5.176 (1 H, dd, J = 7.6 and 7.6 Hz, H-13), 2.906 (1 H, m, H-3), 2.681 (1 H, m, H-3), 2.494 (1 H, ddd, *J* = 14.0, 7.0, and 7.0 Hz, H-12), 2.371 (1 H, ddd, *J* = 14.0, 7.0, and 7.0 Hz, H-12), 2.278 (1 H, m, H-6), 1.871 (1 H, m, H-7), 1.748 (3 H, s, H-25), 1.748 (3 H, s, H-26), 1.630 (3 H, s, H-27), 1.338 (1 H, m, H-7), 1.067 (3 H, s, H-23), and 0.925 (3 H, s, H-24); LR-ESIMS m/z1582.4  $[M + Na]^+$  (calcd for  $C_{78}H_{90}F_{12}O_{19}Na$ , 1582.6). Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD) of **4b**:  $\delta_{\rm H}$  5.664 (1 H, ddd, J = 9.0, 6.0, and 6.0), 5.480 (1 H, br s, H-4), 5.480 (1 H, d, J = 9.0 Hz, H-10), 5.261 (1 H, dd, J = 8.5 and 4.5 Hz, H-8), 5.073 (1 H, dd, J = 7.0 and 7.0 Hz, H-13), 2.936 (1 H, m, H-3), 2.716 (1 H, m, H-3), 2.391 (1 H, ddd, J = 14.0, 7.0, and 7.0 Hz, H-12), 2.298 (1 H, m, H-6), 2.282 (1 H, m, H-12), 1.910 (1 H, m, H-7), 1.774 (3 H, s, H-25), 1.610 (3 H, s, H-26), 1.573 (3 H, s, H-27), 1.462 (1 H, m, H-7), 1.136 (3 H, s, H-23), and 1.018 (3 H, s, H-24); LR-ESIMS m/z 1582.4 [M + Na]<sup>+</sup> (calcd for C<sub>78</sub>H<sub>90</sub>F<sub>12</sub>O<sub>19</sub>Na, 1582.6). Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) of

7a:  $\delta_{\rm H}$  4.775 (1 H, m, H-19), 2.442 (1 H, m, H-21), 1.895 (1 H, m, H-20), 1.843 (1 H, m, H-21), 1.743 (1 H, m, H-17), 1.582 (1 H, m, H-20), 1.472 (2 H, m, H-16), 1.458 (3 H, s, H-30), 0.983 (3 H, s, H-28), and 0.860 (3 H, s, H-29); LR-ESIMS *m*/*z* 1030.4 [M + Na]<sup>+</sup> (calcd for C<sub>54</sub>H<sub>68</sub>F<sub>6</sub>O<sub>11</sub>Na, 1030.5). Selected <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) of 7b:  $\delta_{\rm H}$  4.784 (1 H, m, H-19), 2.571 (1 H, br s, H-21), 1.957 (1 H, m, H-20), 1.881 (1 H, m, H-21), 1.720 (1 H, m, H-20), 1.694 (1 H, m, H-17), 1.493 (3 H, s, H-30), 1.387 (2 H, m, H-16), 0.826 (3 H, s, H-28), and 0.799 (3 H, s, H-29); LR-ESIMS *m*/*z* 1030.4 [M + Na]<sup>+</sup> (calcd for C<sub>54</sub>H<sub>68</sub>F<sub>6</sub>O<sub>11</sub>Na, 1030.5).

Acid Hydrolysis and GC Analysis of Compound 4. A solution of 4 (4.0 mg) in 3 N HCl (0.5 mL) was stirred at 80 °C for 5 h. After being cooled to room temperature, the solution was concentrated by evaporation under a stream of N2. The residue was redissolved in a solution of L-cysteine methyl ester hydrochloride (2.3 mg) in pyridine (0.5 mL), and the solution was stirred at 60 °C for 1.5 h. After being cooled and concentrated, the mixture was treated with hexamethyldisilazane (HMDS) in TMSCl (50  $\mu$ L, v/v = 2:1) in pyridine (0.5 mL), and the solution was stirred at 60 °C for 30 min. After drying the solution with a stream of N<sub>2</sub>, the residue was separated with H<sub>2</sub>O and  $CH_2Cl_2$  (1 mL, v/v = 1:1). The  $CH_2Cl_2$  layer was analyzed by GC using an HP5 column (0.32 mm  $\times$  30 m). The injector and detector were both held at 200 °C. A temperature gradient was applied to the GC oven; the initial temperature was maintained at 60 °C for 3 min, then ramped to 200 at 4 °C/min, and maintained at 200 °C for 3 min. A peak corresponding to a hydrolysate sugar derivative was detected at 31.89 min. Retention times for authentic samples after being treated simultaneously with HMDS/TMSCl were 31.87 (D-galactose) and 30.58 min (L-galactose), respectively. Co-injection of the hydrolysate with the authentic silvlated D-galactose gave single peaks at 31.90 min.

**Biological Assays.** Cytotoxicity assays were performed in accordance with the protocols in refs 11 and 12.

# ASSOCIATED CONTENT

#### **Supporting Information**

<sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds **4–12** are available free of charge via the Internet at http://pubs.acs.org.

### AUTHOR INFORMATION

# **Corresponding Author**

\*(J.S.) Tel: 82 2 880 2484. Fax: 82 2 762 8322. E-mail: shinj@ snu.ac.kr. (K.-B.O.) Tel: 82 2 880 4646. Fax: 82 2 873 3112. Email: ohkibong@snu.ac.kr.

# ACKNOWLEDGMENTS

We would like to thank the Basic Science Research Institute in Daegu, Korea, for providing mass spectrometric data. Particular thanks go to the Department of Marine Resources, State of Chuuk, Federated States of Micronesia, for allowing our marine organism research. This work was partially supported by a Midcareer Researcher Program through a National Research Foundation of Korea (NRF) grant (no. 20110018562), funded by the Ministry of Education, Science and Technology and by the Ministry of Land, Transport and Maritime (PM 56091), Korea.

# REFERENCES

(1) Blunt, J. W.; Copp, B. R.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2011**, *28*, 196–268, and earlier reports in the series.

(2) Ksebati, M. B.; Schmitz, F. J.; Gunasekera, S. P. J. Org. Chem. 1988, 53, 3917–3921.

(3) Kitagawa, I.; Kobayashi, M.; Okamoto, Y.; Yoshikawa, M.; Hamamoto, Y. *Tennen Yuki Kagobutsu Toronkai Koen Yoshishu* **1987**, 29, 568–575.

- (4) Schmitz, F. J.; Ksebati, M. B.; Gunasekera, S. P.; Agarwal, S. J. Org. Chem. 1988, 53, 5941–5947.
- (5) Kobayashi, M.; Okamoto, Y.; Kitagawa, I. *Chem. Pharm. Bull.* **1991**, *39*, 2867–2877.
- (6) Espada, A.; Jiménez, C.; Rodríguez, J.; Crews, P.; Riguera, R. *Tetrahedron* **1992**, *48*, 8685–8696.
- (7) Lee, H.-S.; Seo, Y.; Cho, K. W.; Rho, J.-R.; Shin, J.; Paul, V. J. J. Nat. Prod. 2000, 63, 915–919.

(8) Dai, H.-F.; Edrada, R. A.; Ebel, R.; Nimtz, M.; Wray, V.; Proksch, P. J. Nat. Prod. 2005, 68, 1231–1237.

(9) Santalova, E. A.; Denisenko, V. A.; Dmitrenok, P. S.; Berdyshev, D. V.; Stonik, V. A. Nat. Prod. Commun. 2006, 1, 265–271.

(10) Jeon, J.-e.; Bae, J.; Lee, K. J.; Oh, K.-B.; Shin, J. J. Nat. Prod. 2011, 74, 847-851.

- (11) Mosmann, T. J. Immunol. Methods 1983, 65, 55-63.
- (12) Ulukaya, E.; Ozdikicioglu, F.; Oral, A. Y.; Demirci, M. *Toxicology* in Vitro **2008**, *22*, 232–239.